Pomegranate Juice in Treating Patients With Recurrent Prostate Cancer

Inclusion Criteria:

Histologically confirmed adenocarcinoma of the prostate
Must have undergone prior surgery or radiotherapy for the primary tumor
Documented rising prostate-specific antigen (PSA) level, defined by the following criteria:
Absolute level of PSA at least 0.2 ng/mL but less than 5.0 ng/mL
Rising PSA level must be confirmed at least 1 week later
Adequate PSA time points to calculate a PSA doubling time
Gleason score no greater than 7
Age 18 and over
Performance status ECOG 0-1
Life expectancy at least 6 months
No other malignancy within the past 5 years except nonmelanoma skin cancer
No other serious concurrent systemic medical disorders that would preclude study compliance
No known allergy to pomegranate juice
More than 4 weeks since prior participation in another experimental study

Exclusion Criteria:

nodal involvement
evidence of metastatic disease
prior hormonal therapy
concurrent hormonal therapy for rising PSA levels after initial therapy for prostate cancer
concurrent participation in another experimental study
other concurrent systemic or local therapy for prostate cancer
initiation or discontinuation of any new nutritional or dietary supplements during study participation